Polynucleotide Contains Only Ribonucleotide Monomers Patents (Class 435/91.3)
  • Patent number: 11891611
    Abstract: The present invention relates to a method for modulating plant processes said method being characterized in that a plant is fed with an eco-friendly, plant- and/or algae-derived, biostimulant composition comprising exogenous small RNA molecules. In particular, the method of the invention can be used for modulating physiological or pathological plant processes, such plant growth, plant productivity, fruit quality, quality of produce, plant yield, plant response to abiotic stress and plant resistance to diseases or to infections.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: February 6, 2024
    Assignee: VALAGRO S.P.A
    Inventors: Pierdomenico Perata, Elena Loreti, Eleonora Paparelli, Antonietta Santaniello, Giacomo Novi, Alberto Piaggesi
  • Patent number: 11525158
    Abstract: The present invention is concerned with linear double stranded DNA, which is coupled to a single support or a tag at the 3? end of its non-coding strand and methods for producing said linear double stranded DNA. The present invention further relates to the use of said linear double stranded DNA in an RNA in vitro transcription reaction and also to a method for producing RNA in vitro. The present invention also relates to a bioreactor for RNA in vitro transcription.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 13, 2022
    Assignee: CureVac SE
    Inventors: Benyamin Yazdan Panah, Tilmann Roos, Veronika Wagner, Carola Pongratz
  • Patent number: 11491110
    Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe3O4, as well as compositions containing HSS.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: November 8, 2022
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventors: Ayhan Bozkurt, Seyda Tugba Gunday Anil, Firdos Alam Khan, Sultan Akhtar
  • Patent number: 10751426
    Abstract: The present invention provides a composition containing a single-stranded nucleic acid molecule consisting of a nucleotide sequence shown by 5?-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-P-G-3? (SEQ ID NO: 1) (in the sequence, P is a proline derivative linker represented by (I) in the DESCRIPTION) and a buffer, and having the following features: (a) being in the form of a solution at ambient temperature; and (b) a content of the nucleic acid molecule after storage at 25° C., relative humidity 60% for 4 weeks, of not less than 80% relative to the content at the time of start of the storage.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 25, 2020
    Assignees: BONAC CORPORATION
    Inventors: Taimu Yamada, Hidekazu Toyofuku, Kohei Tahara, Risako Onodera, Hirofumi Takeuchi
  • Patent number: 10745701
    Abstract: The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular. Therapeutic modalities include immunotherapy and anti-sense therapy. Prognosis is determined by measuring the number of copies of the metadherin gene in the patient's cells.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 18, 2020
    Assignee: The Trustees Of Princeton University
    Inventors: Yibin Kang, Guohong Hu
  • Patent number: 10738081
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 11, 2020
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10689713
    Abstract: The invention provides a lysis reagent for lysing red blood cells, thereby releasing a target, such as RNA from a parasitic organism, in a form suitable for analysis. The reagent includes at least ammonium chloride and an anionic detergent, and may include an anti-coagulant. The reagent serves to lyse red blood cells, protect the released target from degradation in the lysate, and is compatible with subsequent steps for analysis of the target such as target capture, amplification, detection, or sequencing.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: June 23, 2020
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Jijumon Chelliserry, Kui Gao, Jeffrey M. Linnen
  • Patent number: 10202605
    Abstract: The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular. Therapeutic modalities include immunotherapy and anti-sense therapy. Prognosis is determined by measuring the number of copies of the metadherin gene in the patient's cells.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 12, 2019
    Assignee: The Trustees of Princeton University
    Inventors: Yibin Kang, Guohong Hu
  • Patent number: 10131944
    Abstract: The invention also encompasses novel structures and methods comprising providing a molecular adapter for capture and manipulation of transfer RNA. The adaptor is bound to a tRNA molecule. The adaptor may be a cholesterol-linked DNA adapter oligonucleotide. The invention is useful in sequencing, identification, manipulation and modification of tRNA.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: November 20, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Bernick, Andrew Smith
  • Patent number: 10093989
    Abstract: The invention provides a lysis reagent for lysing red blood cells, thereby releasing a target, such as RNA from a parasitic organism, in a form suitable for analysis. The reagent includes at least ammonium chloride and an anionic detergent, and may include an anti-coagulant. The reagent serves to lyse red blood cells, protect the released target from degradation in the lysate, and is compatible with subsequent steps for analysis of the target such as target capture, amplification, detection, or sequencing.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: October 9, 2018
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Jijumon Chelliserry, Kui Gao, Jeffrey M. Linnen
  • Patent number: 9752172
    Abstract: Methods and kits are provided for performing multiple rounds of sense RNA synthesis. The sense RNA molecules can be used in various research and diagnostic applications, such as gene expression studies involving nucleic acid microarrays.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: September 5, 2017
    Assignee: Genisphere, LLC
    Inventors: Robert C. Getts, Kelly Sensinger, James Kadushin
  • Patent number: 9732337
    Abstract: The instant invention provides polyvalent RNA nanoparticles comprising RNA motifs as building blocks that can form RNA nanotubes. The polyvalent RNA nanoparticles are suitable for therapeutic or diagnostic use in a number of diseases or disorders.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: August 15, 2017
    Assignees: The United Stated of America, as represented by the Secretary, Department of Health & Human Services, The Regents of the University of California
    Inventors: Bruce A. Shapiro, Yaroslava G. Yingling, Eckart Bindewald, Wojciech Kasprzak, Luc Jaeger, Isil Severcan, Cody Geary, Kirill Afonin
  • Patent number: 9670138
    Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 6, 2017
    Assignee: BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
    Inventor: Esther Priel
  • Patent number: 9611505
    Abstract: During RNA isolation carrier nucleic acids such as polyA-RNA are used in order to increase the yield of the isolated RNA. The carrier nucleic acids may lead to high molecular weight products which may interfere in subsequent steps, such as reverse transcription, PCR and gel electrophoresis. The present invention therefore refers to a method and a kit for reverse transcription and the use of a blocking nucleic acid molecule for blocking the carrier polyA-RNA.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: April 4, 2017
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Bergmann, Stephanie Froehner
  • Patent number: 9506075
    Abstract: In one aspect, the invention relates to a transgenic bioluminescent plant including an expressible heterologous nucleotide sequence comprising a bacterial LUX operon, which includes LUX A, LUX B, LUX C, LUX D, LUX E, and LUX G genes, wherein the heterologous nucleotide sequence is expressed to render the plant bioluminescent.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: November 29, 2016
    Assignee: BioGlow, LLC
    Inventor: Alexander Krichevsky
  • Patent number: 9340779
    Abstract: The present invention relates to the use of HSPC117 molecules as RNA ligase, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: May 17, 2016
    Assignee: IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Johannes Popow, Stefan Weitzer, Javier Martinez, Karl Mechtler, Alexander Schleiffer
  • Patent number: 9334530
    Abstract: Methods of amplifying nucleic acid on a solid support are described. Beads and template, each in known concentrations, are employed so a range of template to bead ratios can be exploited. Where the beads contain primers, the template can be amplified. After amplification, non-covalently bound template is removed, so as to leave beads with extended primers (or beads with primers that were not extended).
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: May 10, 2016
    Assignee: AmberGen, Inc.
    Inventors: Mark J. Lim, Kenneth J. Rothschild
  • Patent number: 9067964
    Abstract: The use of at least one nucleic acid based nuclear localization signal including a natural or synthetic m3G-CAP is shown to increase transmembrane transport of a molecular cargo, in particular large molecules, into the nucleus. The use of natural and synthetic m3G-CAP is disclosed and the effect shown with a natural RNA 5? end nuclear localization signal composed of a 2,2,7-trimethylguanosine CAP (m3G-CAP) coupled to fluorescent Streptavidin in one example, and an antisense oligonucleotide in another. A methylenephosphonate modified m3G-CAP is shown to have improved stability in human serum and in cytosolic extract.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: June 30, 2015
    Assignee: Oligomer Sciences AB
    Inventors: Edvard Smith, Pedro Moreno, Roger Strömberg, Malgorzata Wenska
  • Publication number: 20150141265
    Abstract: The present invention relates to compositions and methods useful for analyzing lariat RNA, which plays a role in the regulation of gene expression. A sample of RNA is specifically treated to remove linear mRNA and enrich for lariat RNA. The enriched lariat RNA sample may be analyzed further to identify introns, branch point sequences, alternative splicing patters, and gene transcription levels. The enriched lariat RNA sample may also be exploited as a detection or compound screening tool, as well as other uses.
    Type: Application
    Filed: October 22, 2014
    Publication date: May 21, 2015
    Inventor: Thomas Matthew Menees
  • Publication number: 20150141492
    Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
    Type: Application
    Filed: September 3, 2014
    Publication date: May 21, 2015
    Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
  • Publication number: 20150132805
    Abstract: This invention generally relates to a composition and its production method useful for developing drugs and/or therapies for enhancing wound healing, in particular scarless wound healing. Particularly, the present invention teaches the essential processes necessary for producing and purifying embryonic stem cell (ESC)-specific RNA compositions, such as messenger RNAs (mRNA), microRNA precursors (pre-miRNA), and small hairpin RNAs (shRNA), which are useful for treating human diseases and lesions.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Applicant: MELLO BIOTECH TAIWAN CO., LTD.
    Inventors: David TS WU, Shi-Lung LIN, Jack S.K. CHEN
  • Publication number: 20150133318
    Abstract: The instant invention is based, at least in part, on the identification of novel methods for the enzymatic enrichment of capped RNAs. The invention provides, e.g., methods for enrichment of capped RNAs, kits for making such capped RNAs, and compositions of enriched RNAs or cDNA libraries derived therefrom.
    Type: Application
    Filed: April 24, 2014
    Publication date: May 14, 2015
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Craig C. MELLO, Weifeng GU
  • Publication number: 20150132848
    Abstract: The present invention relates to a method for producing pools of siRNA molecules suitable for RNA interference.
    Type: Application
    Filed: April 25, 2013
    Publication date: May 14, 2015
    Inventors: Gunter Meister, Michael Hannus
  • Patent number: 9005930
    Abstract: The present invention relates to kits and methods for efficiently generating 5? capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production of 5?-capped RNA having a modified cap nucleotide and for in vitro or in vivo production of polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate, and methods and kits for using a capping enzyme system and modified cap nucleotides for labeling uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate with detectable dye or enzyme moieties.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 14, 2015
    Assignee: Cellscript, LLC
    Inventors: Jerome Jendrisak, Ronald Meis, Gary Dahl
  • Publication number: 20150094209
    Abstract: The present invention provides autonomous replication sequences (ARSs) isolated from Nannochloropsis that support the replication of episomal DNA molecules (EDMs) in eukaryotic cells. The ARSs and EDMs provided herein can be used for expressing genes in organisms including algae and heterokonts.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 2, 2015
    Applicant: Synthetic Genomics, Inc.
    Inventors: Peter DeHoff, Leah Soriaga, Srividya Akella
  • Publication number: 20150087027
    Abstract: The present invention is directed to methods and compositions for adding tails of specific lengths to a substrate polynucleotide. The invention also contemplates methods and compositions for immobilization of tailed substrates to a solid support. The disclosure contemplates that the attenuator molecule is any biomolecule that associates with a tail sequence added to a substrate polynucleotide and controls the addition of a tail sequence to the 3? end of the substrate polynucleotide. The sequence that is added to the substrate polynucleotide is referred to herein as a tail sequence, or simply a tail, and the process of adding a nucleotide to a substrate polynucleotide is referred to herein as tailing.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 26, 2015
    Inventors: Vladimir Makarov, Laurie Kurihara
  • Patent number: 8951757
    Abstract: The present invention relates to a method for the preparation of a labeling agent derived from one type of tRNA prepared by in vitro transcription, which is usable for non-radioactive selective labeling of target proteins produced by in vitro translation with fluorophore or biotin; and a method for selective labeling of target proteins produced by in vitro translation using the labeling agent without labeling pre-existing proteins in the reaction mixture.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: February 10, 2015
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, SooYoun Jun, SangHyeon Kang
  • Publication number: 20150038554
    Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
    Type: Application
    Filed: October 20, 2014
    Publication date: February 5, 2015
    Inventor: Bob Dale Brown
  • Patent number: 8945847
    Abstract: A method of ascertaining the bio-safety of an agent is disclosed.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: February 3, 2015
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Nissim Benvenisty, Yoav Mayshar, Ofra Yanuka
  • Publication number: 20150010950
    Abstract: The invention provides a novel truncated mutated T4 RNA ligase 2. In addition, methods are provided for ligating pre-adenlylated donor molecules to the 3? hydroxyl group of RNA in the absence of ATP using the ligase.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 8, 2015
    Inventors: Thomas Tuschl, Janos Ludwig, Yi Pei, Carolina Lin
  • Patent number: 8927245
    Abstract: Provided herein is a method of preparing an RNA sample comprising: a) obtaining an RNA sample comprising: i. long RNA molecules that may be unfragmented or fragmented to contain 5?-OH group and a 2?-3?-cyclic phosphate group; and ii. short RNA molecules that comprise a 5? phosphate group and a 3? OH group; and b) contacting the RNA sample with an adaptor comprising either a 2?-PO group and 3?-OH group or a 2?,3?-cyclic phosphate group in the presence of a eukaryotic tRNA ligase, thereby producing a ligated RNA sample in which a) the short RNA molecules are selectively ligated to the adaptor or b) the short RNA molecules and long RNA fragments are selectively ligated to the adaptor.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: January 6, 2015
    Assignee: Agilent Technologies, Inc.
    Inventors: Gusti Zeiner, Robert A. Ach
  • Publication number: 20140369988
    Abstract: Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU.
    Type: Application
    Filed: April 23, 2014
    Publication date: December 18, 2014
    Inventors: Masayori Inouye, Yoshihiro Yamaguchi
  • Publication number: 20140373194
    Abstract: The present invention relates in generally to RNAi and its use in gene silencing. In particular, the present invention relates to methods and constructs for delivering double stranded RNA (dsRNA) to pest organisms.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 18, 2014
    Applicant: DEVGEN N.V.
    Inventors: Thierry Andre Olivier Eddy Bogaert, Richard Zwaal, Geert Plaetinck, Jan Octaaf De Kerpel, Titus Jan Kaletta
  • Publication number: 20140348893
    Abstract: The present invention describes a new non-compound based approach for insect and/or arachnid control. The present inventors have identified for the first time novel targets for RNAi, which can effectively control insect and/or arachnid pest populations. Accordingly, the invention provides both nucleotide and amino acid sequences for the novel targets. Also provided are RNA constructs including double stranded RNA regions for mediating RNAi in insects, DNA constructs, expression vectors, host cells and compositions for controlling insects and/or arachnids using RNAi. Finally, the invention also provides for the use of the constructs, vectors, host cells and compositions in control of insects and/or arachnids populations and suitable kits for use in an RNAi based method of controlling insect and/or arachnid pests.
    Type: Application
    Filed: May 27, 2014
    Publication date: November 27, 2014
    Applicant: DEVGEN NV
    Inventor: Titus Jan KALETTA
  • Publication number: 20140328825
    Abstract: The present invention relates to compositions, kits and methods for making and using RNA compositions comprising in vitro-synthesized ssRNA inducing a biological or biochemical effect in a mammalian cell or organism into which the RNA composition is repeatedly or continuously introduced. In certain embodiments, the invention provides compositions and methods for changing the state of differentiation or phenotype of a human or other vertebrate cell. For example, the present invention provides mRNA and methods for reprogramming cells that exhibit a first differentiated state or phenotype to cells that exhibit a second differentiated state or phenotype, such as to reprogram human somatic cells to pluripotent stem cells.
    Type: Application
    Filed: December 31, 2012
    Publication date: November 6, 2014
    Inventors: Judith Meis, Anthony Person, Cynthia Chin, Jerome Jendrisak, Gary Dahl
  • Publication number: 20140329703
    Abstract: The present invention provides improved methods and compositions for RNA isolation. In particular embodiments the present invention concerns the use of methods and compositions for the isolation of full-length RNA from fixed tissue samples. The present invention provides methods for digesting and extracting RNA from a fixed tissue sample.
    Type: Application
    Filed: March 12, 2014
    Publication date: November 6, 2014
    Applicant: Applied Biosystem, LLC
    Inventors: Richard CONRAD, Emily Zeringer
  • Patent number: 8859229
    Abstract: A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates. This RNA can efficiently transfect different kinds of cells. This approach results in increased efficiency (fidelity and productivity) of mRNA synthesis and is less time consuming because it does not require cloning, and also consequently eliminates the unwanted errors and effects related to RNA made on DNA templates obtained with cloning techniques. The results of transfection of RNAs demonstrate that RNA transfection can be very effective in cells that are exceedingly difficult to transfect efficiently with DNA constructs. The method can be used to deliver genes into cells not- or only poorly transfectable for DNA, in vitro and in vivo.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: October 14, 2014
    Assignee: Yale University
    Inventors: Peter M. Rabinovich, Sherman M. Weissman, Marina E. Komarovskaya, Erkut Bahceci
  • Patent number: 8846350
    Abstract: The present invention provides methods and kits for determining which microRNAs bind to a target mRNA where the methods comprise the steps of (a) creating a bait sequence from the target mRNA, where the bait sequence comprises a label that binds to a binding agent; (b) adding a mixture of microRNAs to the bait sequence; (c) separating the microRNAs that bind to the bait sequence from those microRNAs that do not bind; and (d) identifying the microRNAs that bind to the bait sequence, wherein the microRNAs identified are those that bind to the target mRNA.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: September 30, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Simon D. Spivack, Miao Shi, Weiguo Han
  • Patent number: 8846348
    Abstract: The present invention relates to kits and methods for efficiently generating 5? capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production of 5?-capped RNA having a modified cap nucleotide and for in vitro or in vivo production of polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate, and methods and kits for using a capping enzyme system and modified cap nucleotides for labeling uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate with detectable dye or enzyme moieties.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: September 30, 2014
    Assignee: CellScript, LLC
    Inventors: Jerome Jendrisak, Ronald Meis, Gary Dahl
  • Patent number: 8822168
    Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 2, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
  • Patent number: 8809022
    Abstract: The invention provides a novel truncated mutated T4 RNA ligase 2. In addition, methods are provided for ligating pre-adenlylated donor molecules to the 3? hydroxyl group of RNA in the absence of ATP using the ligase.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: August 19, 2014
    Assignee: The Rockefeller University
    Inventors: Thomas Tuschl, Janos Ludwig, Yi Pei, Carolina Lin
  • Publication number: 20140221248
    Abstract: The present invention relates to kits and methods for efficiently generating 5? capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production of 5?-capped RNA having a modified cap nucleotide and for in vitro or in vivo production of polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate, and methods and kits for using a capping enzyme system and modified cap nucleotides for labeling uncapped RNA comprising primary RNA transcripts or RNA having a 5?-diphosphate with detectable dye or enzyme moieties.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 7, 2014
    Applicant: CELLSCRIPT, LLC
    Inventors: Jerome Jendrisak, Ronald Meis, Gary Dahl
  • Publication number: 20140206751
    Abstract: Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided.
    Type: Application
    Filed: January 27, 2014
    Publication date: July 24, 2014
    Applicant: CITY OF HOPE
    Inventors: John J. ROSSI, Nan-Sook LEE
  • Publication number: 20140179539
    Abstract: Compositions and methods are provided for ligating polynucleotides having a length that is greater than 8 nucleotides on an RNA splint. The ligation reaction provides consistent results in high or low ATP concentrations. The reaction can occur rapidly and is generally at least 10 fold more efficient than T4DNA ligase under optimal conditions for T4DNA ligase and the reaction time is less than 6 hours for example, less than 1 hour.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 26, 2014
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Gregory Lohman, Thomas C. Evans
  • Publication number: 20140087427
    Abstract: The invention relates to a new double-stranded RNA endoribonuclease, its derivative and/or variant, which has a loop locating in and interacting with the major groove of the double-stranded RNA, exhibiting sequence specific properties in the double-stranded RNA cleavage.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 27, 2014
    Applicant: Miedzynarodowy Instytut Biologii Molekulamej I Komorkowej
    Inventors: Janusz Marek Bujnicki, Krzysztof Jerzy Skowronek, Dariusz Pianka, Agata Agnieszka Sulej
  • Publication number: 20140087426
    Abstract: This application provides transcription activator-like effector nucleases (TALENs), polynucleotide sequences encoding the TALENs, expression cassettes for producing TALENs to target cleavage of nucleic acids, and methods of producing and using the TALENs.
    Type: Application
    Filed: September 24, 2013
    Publication date: March 27, 2014
    Applicant: The Chinese University of Hong Kong
    Inventors: Yun LIU, Christopher H.K. Cheng
  • Patent number: 8647637
    Abstract: Immunogenic compositions and broad-spectrum vaccines containing newly identified isolates of canine distemper virus (CDV) collected from a geographic area are provided. The newly identified isolates exhibit attributes of both European wildlife lineage CDV and one or both of Arctic and American-2 lineage CDV. Therefore, the vaccines are broadly protective against infection with European wildlife lineage CDV and either Arctic lineage CDV or American-2 lineage CDV, or both Arctic and American-2 lineage CDV.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: February 11, 2014
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Sanjay Kapil
  • Publication number: 20140024081
    Abstract: The present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding an infectious RNA molecule encoding a live viral strain of a dengue 3 virus (DV3), wherein said nucleotide sequence is the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence having at least 99% identity with the nucleotide sequence of SEQ ID NO.1.
    Type: Application
    Filed: March 7, 2013
    Publication date: January 23, 2014
    Applicant: ARBOVAX, INC.
    Inventors: KATHERINE M. SMITH, RAQUEL HERNANDEZ
  • Publication number: 20140005254
    Abstract: The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 2, 2014
    Applicant: EGEN, INC.
    Inventor: EGEN, INC.
  • Publication number: 20140004154
    Abstract: A biologically active RNA—alkali metal—dication formulation, a pharmaceutical composition containing the complexes, and methods of producing the same. The formulation is particularly useful to introduce RNA and an attached cargo into cells allowing its biological intracellular activities: e.g. immunostimulation (immunomodulation), RNA interference or gene expression.
    Type: Application
    Filed: June 17, 2013
    Publication date: January 2, 2014
    Inventor: Steve Pascolo